ArticleJournal of asthma and allergy2026
Assessment of Inhaled Corticosteroid Adherence in Adults with Severe Asthma Receiving Biologic Therapy: A Retrospective Observational Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inhaled corticosteroids (ICS) remain the cornerstone of long-term asthma management. However, adherence to inhaled therapy is frequently suboptimal, even among patients with severe asthma. Biologic therapies substantially improve clinical outcomes, which may unintentionally influence adherence to maintenance inhaler therapy. Objective: To evaluate adherence to inhaled controller therapy in adults with severe asthma receiving biologic treatment and to identify clinical factors associated with inhaler non-adherence. Methods: This single-center retrospective observational study included 173 adults with severe asthma receiving anti-IgE or anti-IL-5/IL-5Rα biologic therapy for at least 12 months. Adherence during the 12-month biologic treatment period was assessed using pharmacy dispensing records (PDR) and the 10-item Test of Adherence to Inhalers (TAI). Non-adherence was defined as medication possession ratio (MPR) <80% and/or TAI score ≤45. Baseline Asthma Control Test (ACT) scores and FEV Results: Overall, 49.1% of patients were classified as non-adherent when both methods were considered. Non-adherence rates were 38.2% according to PDR and 29.5% according to TAI (TAI ≤45). Agreement between methods was fair (κ = 0.37, p < 0.001). Higher baseline ACT scores measured prior to biologic initiation were independently associated with inhaler non-adherence (OR 1.26, 95% CI 1.15-1.38, p < 0.001). FEV Conclusion: Inhaler non-adherence remains prevalent among patients with severe asthma receiving biologic therapy. Higher baseline ACT scores independently predict this risk. Routine multidimensional adherence assessment and structured patient education remain essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.